What top creators are saying about Precigen Inc.(PGEN)

Its shares fell about 29% as Inovio's RRP drug approval was seen as a competitive challenge to Precigen's similar treatment.

Inovio's approved RRP drug was described as a competitor to a Precigen product, creating a potential competitive risk; the effect on future sales was not quantified.

A speaker said they liked the company and had been early to the stock, but provided no supporting analysis.

Martin said he had been early to Precigen but gave no current rating or explanation of the original thesis.

Speaker is bullish following a surprise early FDA approval and sees significant long-term revenue potential, but notes the company will likely need to raise capital.

The speaker is taking a 'very small, long position' not out of conviction, but as a way to force deeper research and monitoring of the stock.

Presents a speculative opportunity with a binary PDUFA date; the bull case rests on strong clinical data, while the bear case is rooted in the company's poor historical reputation.